argenx
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Netherlands · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Laarderhoogtweg 25, Amsterdam, North Hol...Phone Number
+31107038441Website
www.argenx.comRevenue
$4.7 BillionStock Symbol
ARGXIndustry
About argenx
Argenx SE is a global immunology biopharmaceutical company developing antibody-based therapies for severe autoimmune diseases. Its lead product, VYVGART (efgartigimod), an FcRn blocker, is approved in 30+ countries for generalized myasthenia gravis, CIDP, and ITP, generating $4.2B in 2025 sales. The pipeline includes empasiprubart (complement inhibitor) and adimanebart (MuSK agonist), advancing toward "Vision 2030": 50,000 patients treated, 10 labeled indications.Explore more
argenx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
argenx Tech Stack
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding argenx
Sign Up For FreeTo access detailed company insights
Argenx SE is a global immunology biopharmaceutical company developing antibody-based therapies for severe autoimmune diseases. Its lead product, VYVGART (efgartigimod), an FcRn blocker, is approved in 30+ countries for generalized myasthenia gravis, CIDP, and ITP, generating $4.2B in 2025 sales. The pipeline includes empasiprubart (complement inhib... Read More
